Billboards across Salt Lake valley show alarming health of Great Salt Lake
, a Utah-based water policy and advocacy non-profit group, has placed billboards throughout Salt Lake County, live tracking the lake's water levels. As of Feb. 10, the meter showed the Great Salt Lake's water level at 38%, placing it just shy of 'critical' and bordering 'collapse.'
Scientists and those advocating for the preservation of the Great Salt Lake have said that 4,198 feet is the minimum healthy level for the lake though its natural volume is 4,207 feet. The 38% reflected on the billboards on Monday compares the current lake level to its natural volume.
Dr. Ben Abbott, a professor of ecology at BYU and Grow the Flow executive director, said the billboards help bring the Great Salt Lake – which is largely out of sight for most Utahns – into view.
Bill seeks to ban planes from releasing chemicals for 'weather geoengineering'
'The first step toward solving a problem is awareness,' said Abbott. 'No billboard can capture all of the details of the health of the lake, but just seeing the current lake volume gives Utahns a way to access the situation. Israel did this with the Sea of Galilee, and it really helped the whole community get on board.'
Abbott told ABC4.com that the work being done to save the Great Salt Lake is 'unprecedented.' He explained that there are hundreds of saline lakes all around the world and nearly all are in decline.
'There's not a single one that's been restored after it slipped into decline,' Abbott said. 'So, for our community to accomplish this really unprecedented pioneering act, we're all going to know where we are. And so, we hope that these billboards are just kind of something daily that you look at, you know, the way you would look at the weather.'
Over the year, using data from the United States Geological Survey, Utahns will be able to see the small changes in the lake. Abbott said the billboards will reflect when the water levels go up during the spring runoff and when the levels decline during the hot summer months.
Missing 14-year-old snowmobiler found after overnight search along Utah-Idaho border
The Great Salt Lake reached and while helped alleviate the lake's declining health, Abbott said Utah can't rely on weather to save the lake. He said it would take cities, farmers, industries, and individuals each doing their small part to rescue the lake.
But he likened the race to save the Great Salt Lake to a spring that is immediately followed by a marathon.
'We need a bunch of actions right now to get to the lake to a healthy level, and then long term, we've got to put in place the structural changes that we need to keep it in at a healthy range,' said Abbott. 'Great Salt Lake is a fixture of our community. It's a global landmark. Millions of birds come here, billions of dollars are produced by the lake, and, most importantly to me, it's a sign of our values and our commitment as a community to be caretakers over creation.'
To learn more about the billboards and how they calculate the percentage shown, visit
Connor Comeau contributed to this report.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Is Wall Street Bullish or Bearish on Thermo Fisher Scientific Stock?
With a market cap of $155.6 billion, Thermo Fisher Scientific Inc. (TMO) stands as a global leader in serving science, providing cutting-edge technologies, services, and solutions that drive research and enhance healthcare. The Waltham, Massachusetts-based company operates through four core segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services. Shares of TMO have underperformed the broader market, dropping 19% over the past year and 6% in 2025. In comparison, the broader S&P 500 Index ($SPX) has gained 16.4% over the past 52 weeks and 9.7% on a YTD basis. More News from Barchart Lyft Generates Huge FCF Margins - LYFT Stock Is Too Cheap Powell, Trump Talks and Other Can't Miss Items this Week 'My Kid Will Never Ever Be Smarter Than an AI': OpenAI's Sam Altman Warns Most Kids Won't Know a World Without AI Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Looking closer, the stock has also trailed behind the Health Care Select Sector SPDR Fund's (XLV) 10.8% decline over the past 52 weeks and a marginal fall year-to-date. Thermo Fisher released its Q2 2025 earnings on July 23, and its shares popped 9.1%. It reported revenue of $10.85 billion, a 3% year-over-year increase (with 2% organic growth). Adjusted EPS was $5.36, compared to $5.37 in the prior year, while adjusted operating income rose to $2.38 billion from $2.35 billion in the year-ago quarter. Thermo Fisher also highlighted the launch of next-generation instruments, including Orbitrap Astral Zoom, Orbitrap Excedion Pro, and the Krios 5 Cryo-TEM, as well as an expanded DynaDrive single-use bioreactor portfolio. For the fiscal year ending in December 2025, analysts expect TMO's adjusted EPS to grow 3% year-over-year to $22.52. The company's earnings surprise history is promising. It topped the consensus estimates in the last four quarters. Among the 26 analysts covering the stock, the consensus rating is a 'Strong Buy.' That's based on 18 'Strong Buy' ratings, three 'Moderate Buys,' and five 'Holds.' This configuration has been stable over the past months. On July 28, UBS analyst Dan Leonard downgraded Thermo Fisher to 'Neutral' from 'Buy,' cutting the price target to $460 from $500, citing concerns that persistent headwinds could weigh on life sciences R&D, which accounts for about half of the company's sales. UBS also forecast 2026 organic sales growth of 4%, 200 basis points below consensus, and reduced its longer-term outlook. TMO's mean price target of $553.60 implies a modest potential upside of 13.2% from the current price levels. Similarly, the Street-high price target of $650 indicates that the stock could soar by 32.9%. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
6 hours ago
- Yahoo
Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics
Biodesix recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer LOUISVILLE, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leader in personalized diagnostics, announced that the company is designated as a Thermo Fisher Scientific Center of Excellence (COE) as part of Thermo Fisher's collaborative initiative to advance NGS-based diagnostics. The services provided to Thermo Fisher are an example of Biodesix Development Services offerings, including customizable options that enable the world's leading life sciences companies, biopharmaceutical, and medical research institutions with scientific, technological, and operational capabilities. As Thermo Fisher announced in July 2025, Biodesix was an instrumental partner in the validation of the Oncomine Dx Express Test leading to the FDA approval of the Genexus Dx Integrated Sequencer. Biodesix Development Services conducted validation studies utilizing its design-controlled laboratory processes, quality management systems, and contributed data generation in support of regulatory submission. 'Working with Thermo Fisher, we continue to forge a path to conquer cancer, and we are delighted to expand our molecular diagnostic and NGS testing capabilities in tissue-based profiling,' said Scott Hutton, CEO at Biodesix. "Being a member of Thermo Fisher's COE network puts us in excellent company with other global groups committed to transforming cancer diagnosis and care. We are excited about the potential to offer the Oncomine Dx Express Test in the future.' Upcoming presentations to learn more about the Thermo Fisher NGS precision oncology solution and how Biodesix will apply the science for its industry clients and healthcare professionals: August 27, 2025 | CAP TODAY | Thermo Fisher Scientific Webinar: Introduction of new FDA approved rapid NGS solution for Companion Diagnostics & tumor profiling in oncology. Speakers: David Chi, PhD, Thermo Fisher Scientific, Bence Sipos, MD, and Gary Pestano, PhD, Chief Development Officer, Biodesix September 15, 2025 | Orlando, FL | College of American Pathologists (CAP) 2025 Annual Meeting | Thermo Fisher-sponsored Panel: "Introduction of new IVD solution for rapid NGS profiling in Oncology". Speakers: Mahmoud Elsayad, MD, FCAP, University of Texas Health, Alison Roos, Thermo Fisher Scientific, and Gary Pestano, PhD, Chief Development Officer, Biodesix About Biodesix:Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world's leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit About the Thermo Fisher COE Network: Thermo Fisher's NGS COE Network partners with leading global institutions to develop, validate, and refine its Ion Torrent™ Oncomine™ solutions portfolio. Through these COEs, Thermo Fisher collaborates with experts to accelerate oncology research, foster strategic alliances, and advance precision medicine. Biodesix Contacts: Media:Natalie St. Denis, Director Corporate Communications, 925-9285 Investors:Chris Brinzey, Partner, 970-2843Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data


Newsweek
10 hours ago
- Newsweek
China Tech CEO Reveals Plans for Humanoid 'Pregnancy Robot'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A robotics entrepreneur says his company is nearing completion of a "pregnancy robot," with a prototype to be ready for sale as early as next year. "Some people don't want to get married but still want a 'wife'; some don't want to be pregnant but still want a child. So one function of our 'robot wife' is that it can carry a pregnancy," said Zhang Qifeng, founder of Guangzhou-based Kaiwa Technology. Why It Matters China has invested heavily in robotics. The country is a leader in industrial robots per capita and has just hosted the first "World Humanoid Robot Games" in Beijing. The push aims to prepare for a shrinking workforce as China becomes a super-aged society. In recent years, it has faced a flagging birth rate, as economic concerns and changing social attitudes push women to have children later than ever—or not at all. A woman touches a humanoid robot during the World Artificial Intelligence Conference at the Shanghai World Expo and Convention Center in Shanghai on July 28, 2025. A woman touches a humanoid robot during the World Artificial Intelligence Conference at the Shanghai World Expo and Convention Center in Shanghai on July 28, 2025. Hector Retamal/AFP via Getty Images Infertility has also risen, to 18 percent in 2020 from 12 percent in 2007, according to a report published by the medical journal The Lancet, with one out of every 5.6 couples of childbearing age facing difficulties conceiving. Newsweek reached out to the Chinese foreign ministry by email with a request for comment. What To Know Surrogacy is illegal in China, but Zhang—who holds a Ph.D. from Nanyang Technological University in Singapore—hopes to work around the ban with robots. "We want to integrate a gestation chamber into a humanoid robot and build an artificial womb so it can carry a full-term pregnancy 'in the normal way,'" Zhang said in an interview last week with the tech outlet Kuai Ke Zhi. A synthetic uterus, which he says is already at a "mature" stage, would serve as an incubator for about 10 months, with nutrients delivered through a tube connected to the umbilical cord. The concept recalls the temperature-controlled "biobag" used in 2017 by researchers at the Children's Hospital of Philadelphia, who simulated amniotic fluid with a warm saline solution and kept premature lambs alive for weeks. What People Are Saying Zhang's interview made waves on Chinese social media, becoming one of the most-trending topics on the microblogging platform Weibo. Many users were intrigued by the technological possibilities but voiced skepticism about the unproven approach and the maximum price point given by Zhang—100,000 yuan (about $14,000), roughly half of Beijing's average annual wage. Experts have also weighed in. "Pregnancy is an extremely complex process, with each step being extremely delicate and critical," said Yi Fuxian, an obstetrician at the University of Wisconsin–Madison who conducts demographic research, He told Newsweek the robot is "likely just a gimmick" and warned of "many health and ethical risks" even if it could ultimately bring a child to term. He noted that the artificial gestation in sheep is not a reliable predictor for much longer-lived humans and "many health risks emerge at different ages, not to mention mental health issues," he said. What To Know Zhang said he has been holding discussions with the Guangdong provincial authorities but it is not clear if the product will be approved for sale.